资讯库
更紧凑的生命科学资讯库。
先搜索，再按来源或主题继续收窄。
哪些宏观因素可能推高沃特世公司（WAZ）股价——投资组合更新报告与专家认可动量交易策略——newser.com
What macro factors could drive Waters Corporation (WAZ) stock higher - Portfolio Update Report & Expert Approved Momentum Trade Ideas newser.com
安捷伦科技公司股价为何保持韧性——止损与每日股票动量报告——newser.com
Why Agilent Technologies Inc. stock stays resilient - Stop Loss & Daily Stock Momentum Reports newser.com
安捷伦科技公司β系数与主要股指对比分析——2025年7月趋势及免费实时市场情绪预警——新闻集锦网
Measuring Agilent Technologies Inc.’s beta against major indices - July 2025 Trends & Free Real-Time Market Sentiment Alerts newser.com
2025年威特斯公司(WAZ)股票能否跑赢能源板块？——投资组合更新报告与长期稳健投资计划 - newser.com
Will Waters Corporation (WAZ) stock outperform energy sector in 2025 - Portfolio Update Report & Long-Term Safe Investment Plans newser.com
KaliVir Immunotherapeutics宣布与罗氏达成临床试验合作与供应协议，共同评估VET3-TGI联合阿特珠单抗（Tecentriq®）治疗晚期实体瘤的效果——雅虎财经报道
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in...
安捷伦科技(AG8)股票是否准备好迎接数字化转型——周投资回顾与基于AI的买卖信号——newser.com
Is Agilent Technologies Inc. (AG8) stock prepared for digital transition - Weekly Investment Recap & AI Based Buy and Sell Signals newser.com
CRISPR/Cas9基因敲入标记技术：简化内源性生物学研究
Understanding the expression, function and dynamics of proteins in their native environment is a fundamental goal that’s common to diverse aspects of molecular and cell...
Freenome与罗氏达成独家协议，扩大技术合作并在美国以外地区开发和商业化癌症筛查检测 - PR Newswire
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S. PR Newswire
新型实验性药物或将改变癌症患者护理方式——独立报
New experimental drug could transform care for cancer patients The Independent
罗氏制药管线进展与股价飙升17%后，是否该重新评估其投资时机？ - simplywall.st
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? simplywall.st
Amylin有望在下一波减肥药浪潮中称雄。
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.